Holen Sie sich die Stockscreener-App
1.65
5.77%
0.09
Handel nachbörslich:
1.62
-0.03
-1.82%
Bioaffinity Technologies Inc Aktie (BIAF) Neueste Nachrichten
Number of shareholders of bioAffinity Technologies, Inc. – NASDAQ:BIAF - TradingView
What's Driving bioAffinity Technologies' Recent Surge - Kavout
Top AIAI (AIAI) Competitors 2026 - MarketBeat
bioAffinity Technologies Inc (BIAF) Stock Price, Quote, News & History - Benzinga
BIAF Stock Price, Quote & Chart | BIOAFFINITY TECHNOLOGIES INC (NASDAQ:BIAF) - ChartMill
bioAffinity Technologies, Inc.Warrant (NQ: BIAFW - FinancialContent
bioAffinity (BIAF) registers 497,483 resale shares, includes 365,603 warrants - Stock Titan
BIAF Stock Slips Post Q1 Earnings Despite Strength in CyPath Lung - The Globe and Mail
[EFFECT] bioAffinity Technologies, Inc. SEC Filing - Stock Titan
bioAffinity reports 300% jump in lung test sales in April - Investing.com UK
bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Ye - PharmiWeb.com
bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026 - 01net
bioAffinity Technologies Reports Record 300% Growth in CyPath® Lung Diagnostic Test Sales in April 2026 - Minichart
bioAffinity CyPath Lung Test Sales Surge Sharply - TipRanks
TradingKey - TradingKey
bioAffinity reports 300% jump in lung test sales in April By Investing.com - Investing.com Australia
bioAffinity Reports Record Monthly CyPath Lung Unit Sales, April Up Nearly 300% - TradingView
Record CyPath Lung growth at bioAffinity (NASDAQ: BIAF) with April unit sales up nearly 300% - Stock Titan
bioAffinity Technologies, Inc. 2026 Q1 10-Q Filing: Financial Results, Risk Factors, and Forward-Looking Statements - Minichart
bioAffinity Technologies reports net loss of USD 3.6M in Q1 2026 - Medical Buyer
bioAffinity Technologies, Inc. 1Q 2026: Revenue $1.35M, EPS $(0.81) — 10-Q Summary - TradingView
BioAffinity Technologies : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Number of shareholders of bioAffinity Technologies, Inc. – NASDAQ:BIAFW - TradingView
Q1 2026 loss deepens at bioAffinity Technologies (NASDAQ: BIAF) - Stock Titan
bioAffinity Technologies Releases Q1 2026 Financial Results - AlphaStreet
BIAF | bioAffinity Technologies, Inc. Common Insider Trading - Quiver Quantitative
bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung - BioSpace
Bioaffinity Technologies IncQ1 2026 net loss $3.6 million or $0.81 per share - marketscreener.com
BioAffinity Technologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
CyPath Lung growth stands out in bioAffinity (NASDAQ: BIAF) Q1 2026 results - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
bioAffinity Shareholders Approve Equity Plan and Capital Measures - The Globe and Mail
Investors in bioAffinity (NASDAQ: BIAF) register 497,483 shares for resale - Stock Titan
8-K: Current report - Moomoo
bioAffinity Technologies (BIAF) wins approval for major equity plan, offerings and reverse split - Stock Titan
BioAffinity stock surges 113.8% in 3 months: What's driving the rally? - MSN
bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment - BioSpace
BIAF Stock Dips After Q3 Earnings Reflect Lower Sales and Wider Loss - MSN
BIAF stock gains as CyPath sales surge 146% in Q1 - MSN
1.19%
0.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):